- List
- By Topic
- On Map
- Search Details

"tuberous sclerosis"
Need help? See RSS Feeds
Choose a feed type:

"tuberous sclerosis" (59 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03422367 | Recruiting | JASPER Early Intervention for Tuberous Sclerosis |
|
|
Interventional | Not Applicable |
|
Other / NIH |
|
|
64 | All | 6 Months to 40 Months (Child) | NCT03422367 | IRB #17-000262 1R01HD090138-01A1 |
JETS | October 24, 2017 | June 15, 2022 | June 15, 2022 | February 5, 2018 | February 23, 2018 |
|
|
2 | NCT01954693 | Active, not recruiting | A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
48 | All | 16 Years to 60 Years (Child, Adult) | NCT01954693 | SPON803-10 2011-004854-25 |
TRON | June 2012 | August 6, 2018 | August 6, 2018 | October 7, 2013 | January 30, 2018 |
|
|
3 | NCT00598455 | Completed | Tuberous Sclerosis Complex Natural History Study: Renal Manifestations |
|
Observational |
|
Other |
|
450 | All | 7 Years to 65 Years (Child, Adult) | NCT00598455 | TS0500008 W81XWH-06-1-0538 |
February 2008 | September 2013 | September 2013 | January 22, 2008 | May 4, 2017 |
|
|||||
4 | NCT02687633 | Unknown † | Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex |
|
|
Interventional | Not Applicable |
|
Other |
|
|
32 | All | 12 Months to 36 Months (Child) | NCT02687633 | 15-000699 | September 2015 | August 2017 | August 2017 | February 22, 2016 | February 22, 2016 |
|
||
5 | NCT01780441 | Active, not recruiting | Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) |
|
Observational |
|
Other / NIH |
|
|
166 | All | 3 Months to 12 Months (Child) | NCT01780441 | IRB-P00005074 1U01NS082320-01 |
January 2013 | February 2019 | December 2019 | January 31, 2013 | February 7, 2018 |
|
||||
6 | NCT03276195 | Recruiting | Studies in Patients With Tuberous Sclerosis Complex |
|
Observational |
|
Other / U.S. Fed |
|
|
1000 | All | Child, Adult, Senior | NCT03276195 | vnarayanan15-016 | May 2016 | December 2019 | December 2021 | September 8, 2017 | March 13, 2018 |
|
||||
7 | NCT01289912 | Completed Has Results |
Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
52 | All | 6 Years to 21 Years (Child, Adult) | NCT01289912 | 10-06-0247 | TSC | January 2011 | December 2014 | December 2014 | February 4, 2011 | January 25, 2018 | January 25, 2018 |
|
8 | NCT02849457 | Recruiting | Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
80 | All | up to 6 Months (Child) | NCT02849457 | PREVeNT 1U01NS092595-01A1 |
December 2016 | May 2020 | May 2021 | July 29, 2016 | May 30, 2017 |
|
||
9 | NCT02887781 | Recruiting | Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France |
|
Observational |
|
Other |
|
|
150 | All | 8 Years and older (Child, Adult, Senior) | NCT02887781 | TSAR (RB 14.055) | TSAR | August 13, 2015 | December 31, 2020 | December 31, 2020 | September 2, 2016 | November 29, 2017 |
|
|||
10 | NCT02104011 | Completed | Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers |
|
|
Interventional | Phase 2 |
|
Other |
|
|
2 | All | 18 Years and older (Adult, Senior) | NCT02104011 | CHUBX 2011/35 | STBETA | May 22, 2015 | November 22, 2017 | November 22, 2017 | April 4, 2014 | January 23, 2018 |
|
|
11 | NCT01713946 | Completed | A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
370 | All | 2 Years to 65 Years (Child, Adult) | NCT01713946 | CRAD001M2304 2011-000860-90 |
EXIST-3 | April 29, 2013 | October 2, 2015 | October 25, 2017 | October 25, 2012 | February 1, 2018 |
|
|
12 | NCT00457808 | Completed | Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM |
|
|
Interventional | Phase 2 |
|
Other |
|
|
25 | All | 18 Years to 65 Years (Adult) | NCT00457808 | CCHMC IRB # 02-10-16 R21CA103486 |
December 2002 | March 2006 | April 9, 2007 | April 9, 2007 |
|
|||
13 | NCT00411619 | Completed Has Results |
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
28 | All | 3 Years and older (Child, Adult, Senior) | NCT00411619 | CCHMC IRB# 06-07-50 | January 2007 | January 2014 | January 2014 | December 14, 2006 | October 20, 2014 | October 20, 2014 |
|
|
14 | NCT01070316 | Completed Has Results |
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
20 | All | 2 Years and older (Child, Adult, Senior) | NCT01070316 | 2009-0998 | January 2010 | April 2016 | April 2016 | February 18, 2010 | March 13, 2017 | September 23, 2016 |
|
|
15 | NCT03363763 | Not yet recruiting | Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
45 | All | 2 Years to 18 Years (Child, Adult) | NCT03363763 | AUCTA-UAP006-PH2 | December 2017 | June 2018 | September 2018 | December 6, 2017 | December 6, 2017 | |||
16 | NCT02544763 | Recruiting | A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
210 | All | 1 Year to 65 Years (Child, Adult) | NCT02544763 | GWEP1521 Blinded Phase 2015-002154-12 |
April 2016 | September 2018 | September 2018 | September 9, 2015 | October 24, 2017 |
|
||
17 | NCT02544750 | Enrolling by invitation | An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
210 | All | 1 Year to 65 Years (Child, Adult) | NCT02544750 | GWEP1521 Open-Label Extension 2015-002154-12 |
August 2016 | September 2020 | September 2020 | September 9, 2015 | October 24, 2017 |
|
||
18 | NCT00490789 | Unknown † | Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
14 | All | 18 Years to 65 Years (Adult) | NCT00490789 | TESSTAL | TESSTAL | October 2005 | September 2009 | September 2009 | June 25, 2007 | April 30, 2008 |
|
|
19 | NCT00789828 | Completed Has Results |
Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
117 | All | Child, Adult, Senior | NCT00789828 | CRAD001M2301 2007-006997-27 |
EXIST-1 | August 2009 | March 2011 | October 2014 | November 13, 2008 | February 3, 2016 | May 1, 2012 |
|
20 | NCT00792766 | Completed | Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
20 | All | 18 Years to 65 Years (Adult) | NCT00792766 | CCHMC IRB# 2008-0333 | December 2008 | September 2013 | September 2013 | November 18, 2008 | September 18, 2013 |
|
||
21 | NCT02962414 | Recruiting | Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
218 | All | 2 Years to 65 Years (Child, Adult) | NCT02962414 | CRAD001M2X02B | June 8, 2017 | April 2, 2027 | January 5, 2028 | November 11, 2016 | August 28, 2017 |
|
||
22 | NCT02098759 | Recruiting | Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex |
|
|
Interventional | Not Applicable |
|
Other |
|
|
100 | All | up to 4 Months (Child) | NCT02098759 | EPISTOP 602391 |
EPISTOP | November 2013 | October 2018 | October 2018 | March 28, 2014 | April 4, 2014 |
|
|
23 | NCT00001975 | Recruiting | Study of Skin Tumors in Tuberous Sclerosis |
|
Observational |
|
NIH / U.S. Fed | 130 | All | 18 Years to 90 Years (Adult, Senior) | NCT00001975 | 000051 00-H-0051 |
January 19, 2000 | January 21, 2000 | April 17, 2018 |
|
||||||||
24 | NCT00790400 | Completed Has Results |
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
118 | All | 18 Years and older (Adult, Senior) | NCT00790400 | CRAD001M2302 2008-002113-48 |
EXIST-2 | April 2009 | June 2011 | November 2015 | November 13, 2008 | February 17, 2017 | August 28, 2012 |
|
25 | NCT02325505 | Recruiting | Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma |
|
Observational |
|
Other / Industry |
|
|
200 | All | Child, Adult, Senior | NCT02325505 | 4147/14/127 | April 2016 | April 2018 | April 2018 | December 25, 2014 | August 22, 2017 |
|
||||
26 | NCT02654340 | Recruiting | Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex |
|
Observational |
|
Other / Industry |
|
|
100 | All | 2 Years and older (Child, Adult, Senior) | NCT02654340 | TSC 06-2015 | TuScCom | March 2015 | March 2020 | March 2020 | January 13, 2016 | July 5, 2017 |
|
|||
27 | NCT02461459 | Recruiting | Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) |
|
Observational |
|
Other / NIH |
|
|
100 | All | 3 Years to 21 Years (Child, Adult) | NCT02461459 | IRB-P00013585 1U54NS092090 |
May 2015 | December 2019 | December 2019 | June 3, 2015 | July 19, 2017 |
|
||||
28 | NCT02634931 | Unknown † | Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
80 | All | 3 Years and older (Child, Adult, Senior) | NCT02634931 | NPC-12G-2 | December 2015 | October 2017 | February 2018 | December 18, 2015 | December 23, 2015 |
|
||
29 | NCT02635789 | Completed | Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
62 | All | 3 Years and older (Child, Adult, Senior) | NCT02635789 | NPC-12G-1 | December 2015 | October 2016 | October 2016 | December 21, 2015 | February 2, 2017 |
|
||
30 | NCT01730209 | Unknown † | Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex |
|
|
Interventional | Phase 2 Phase 3 |
|
Other |
|
|
60 | All | 4 Years to 15 Years (Child) | NCT01730209 | NL38619.078.11 | RAPIT | November 2012 | November 2015 | November 2016 | November 21, 2012 | May 5, 2015 |
|
|
31 | NCT02061397 | Recruiting | Safety of Simvastatin in LAM and TSC |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
10 | Female | 18 Years and older (Adult, Senior) | NCT02061397 | The SOS Trial | SOS | March 2014 | January 2018 | January 2018 | February 12, 2014 | June 14, 2017 |
|
|
32 | NCT00457964 | Completed | RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
36 | All | 18 Years to 65 Years (Adult) | NCT00457964 | CCHMC IRB #2008-0812(04-07-22) | August 2005 | July 2013 | July 2013 | April 9, 2007 | September 25, 2013 |
|
||
33 | NCT02436746 | Unknown † | The Cognitive Variability in NF1 and TSC Monozygotic Twins |
|
Observational |
|
Other |
|
|
116 | All | Child, Adult, Senior | NCT02436746 | MEC-2014-483 | COVANTT | April 2015 | April 2017 | April 2017 | May 7, 2015 | May 7, 2015 |
|
|||
34 | NCT01031901 | Completed | Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) |
|
|
Interventional | Phase 1 |
|
Other |
|
|
52 | All | 13 Years and older (Child, Adult, Senior) | NCT01031901 | HSC-MS-09-0259 | December 2009 | February 2011 | June 2011 | December 15, 2009 | February 27, 2012 |
|
||
35 | NCT01767779 | Active, not recruiting | Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC |
|
Observational |
|
Other |
|
|
40 | All | up to 6 Months (Child) | NCT01767779 | 1P20NS080199-01 | September 2012 | December 2016 | December 2018 | January 14, 2013 | January 9, 2018 |
|
||||
36 | NCT03356769 | Recruiting | Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex |
|
|
Interventional | Phase 2 |
|
Other |
|
|
98 | All | 6 Years to 30 Years (Child, Adult) | NCT03356769 | JS-1425 | November 20, 2017 | November 20, 2019 | November 20, 2020 | November 29, 2017 | November 29, 2017 |
|
||
37 | NCT03140449 | Completed | Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis |
|
|
Interventional | Phase 3 |
|
Other |
|
|
52 | All | 7 Years to 65 Years (Child, Adult) | NCT03140449 | 201306009MINB | September 5, 2013 | November 7, 2016 | April 25, 2017 | May 4, 2017 | May 4, 2017 | |||
38 | NCT02860494 | Not yet recruiting | Topical Everolimus in Patients With Tuberous Sclerosis Complex |
|
|
Interventional | Phase 2 Phase 3 |
|
Other |
|
|
96 | All | up to 2 Years (Child) | NCT02860494 | 69HCL16_0062 | EVEROST | September 2018 | September 2021 | September 2022 | August 9, 2016 | February 26, 2018 |
|
|
39 | NCT01092208 | Terminated | Studies of Autistic Patients: Gene Networks and Clinical Subtypes |
|
Observational |
|
NIH |
|
11 | Male | 4 Years to 18 Years (Child, Adult) | NCT01092208 | 100084 10-CH-0084 |
March 17, 2010 | September 24, 2013 | March 24, 2010 | April 19, 2018 |
|
||||||
40 | NCT03326765 | Not yet recruiting | Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC) |
|
|
Interventional | Not Applicable |
|
Other |
|
|
60 | All | up to 70 Years (Child, Adult, Senior) | NCT03326765 | TSC v 1.0 | November 1, 2017 | November 1, 2019 | November 30, 2019 | October 31, 2017 | October 31, 2017 | |||
41 | NCT01853423 | Completed | Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
11 | All | 3 Years to 45 Years (Child, Adult) | NCT01853423 | UTHSC TSC01 12-2008 |
October 2013 | May 2016 | July 2016 | May 15, 2013 | August 19, 2016 |
|
||
42 | NCT01217125 | Completed | Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis |
|
|
Interventional | Phase 4 |
|
Other |
|
|
18 | All | 10 Years and older (Child, Adult, Senior) | NCT01217125 | EudraCT 2007-005978-30 | October 2008 | May 2011 | May 2011 | October 8, 2010 | March 8, 2012 | |||
43 | NCT01526356 | Completed | Topical Rapamycin to Erase Angiofibromas in TSC |
|
|
Interventional | Phase 2 |
|
Other |
|
|
177 | All | Child, Adult, Senior | NCT01526356 | HSC-MS-11-0501 Department of Defense USAMRMC |
Treatment | May 2012 | August 2014 | August 2014 | February 3, 2012 | June 11, 2015 |
|
|
44 | NCT00989742 | Completed | Doxycycline In Lymphangioleiomyomatosis (LAM) |
|
|
Interventional | Phase 4 |
|
Other |
|
|
24 | Female | 18 Years and older (Adult, Senior) | NCT00989742 | 07061 | July 2009 | January 2013 | January 2013 | October 5, 2009 | December 2, 2015 |
|
||
45 | NCT01266291 | Terminated Has Results |
Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
1 | All | 18 Years and older (Adult, Senior) | NCT01266291 | 811542 | STARS | August 2010 | February 2013 | December 2013 | December 24, 2010 | July 12, 2017 | July 12, 2017 |
|
46 | NCT02451696 | Recruiting | A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD |
|
|
Interventional | Phase 2 |
|
Other |
|
|
30 | All | 2 Years to 40 Years (Child, Adult) | NCT02451696 | 14-00245 | January 2014 | June 2018 | June 2018 | May 22, 2015 | April 13, 2018 |
|
||
47 | NCT01929642 | Completed | Rapalogues for Autism Phenotype in TSC: A Feasibility Study |
|
|
Interventional | Phase 2 |
|
Other |
|
|
3 | All | 2 Years to 30 Years (Child, Adult) | NCT01929642 | AM00037881 | RAPT | July 2013 | July 2016 | August 2016 | August 28, 2013 | January 23, 2018 |
|
|
48 | NCT02201212 | Recruiting | Everolimus for Cancer With TSC1 or TSC2 Mutation |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
30 | All | 18 Years and older (Adult, Senior) | NCT02201212 | 14-229 CRAD001MUS217T |
September 2014 | December 2018 | January 2022 | July 28, 2014 | March 1, 2018 |
|
||
49 | NCT00552955 | Completed | Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women |
|
Observational |
|
NIH |
|
35 | Female | 18 Years to 80 Years (Adult, Senior) | NCT00552955 | 080016 08-H-0016 |
October 26, 2007 | March 21, 2016 | November 2, 2007 | February 14, 2018 |
|
||||||
50 | NCT00001465 | Recruiting | Study of the Disease Process of Lymphangioleiomyomatosis |
|
Observational |
|
NIH | 99999999 | All | 16 Years to 80 Years (Child, Adult, Senior) | NCT00001465 | 950186 95-H-0186 |
September 25, 1995 | November 4, 1999 | March 29, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.